Proteome-Wide Association Study Identifies Plasma β-Glucuronidase as a Causal Risk Protein for Multiple System Atrophy
Objective: This study aims to identify plasma proteins associated with multiple system atrophy (MSA), using a proteome-wide association study (PWAS) and to determine their causal roles…Treatment Stability Across Different ADD-ON Therapies in Fluctuating Parkinson’s Disease
Objective: This study investigates the efficacy and tolerability of selegiline (SL), rasagiline (RS), safinamide (SF), and opicapone (OP) in fluctuating PD patients, focusing on treatment…Does COMT Play a Role in Parkinson’s Disease Susceptibility Across Diverse Ancestral Populations?
Objective: To investigate the relationship between COMT genetic variants and PD risk across diverse ancestries. Background: The enzyme catechol-O-methyltransferase (COMT; OMIM:116790) plays a crucial role…Opicapone Effect on Sleep Disorders in Fluctuating Parkinson’s Disease Patients: Findings from the OASIS Trial
Objective: The OASIS exploratory trial aimed to evaluate the effects of opicapone (OPC) on sleep disorders in Parkinson’s disease (PD) patients with motor fluctuations (MF)…Opicapone Reduces Homocysteine Levels in Patients with Parkinson’s Disease Treated with Levodopa Gel Infusion
Objective: Our study aims to assess the effect of an add-on treatment with catechol-O-methyl transferase (COMT) inhibitor, opicapone, on the plasmatic levels of homocysteine (HCY)…Association between Genetic Polymorphisms and Disease Progression in Parkinson’s disease
Objective: In this study, we aim to elucidate the association between the various haplotypes of the Catechol-O-methyltransferase (COMT) and Monoamine oxidase B (MAO-B) genes, the…Combination COMT inhibitor with Levodopa reduces consumption of vitamin B6
Objective: To investigate changes in Levodopa (LD) pharmacokinetics and changes in homocysteine, vitamin B6, and vitamin B12 in Parkinson's disease (PD) patients receiving LD formulations…Effect of variants in COMT and UGT1A genes on clinical response in patients with Parkinson’s disease treated with opicapone
Objective: To identify genetic variants associated with different clinical responses in patients with Parkinson’s disease(PD) treated with opicapone. Background: Opicapone is a catechol‐O‐methyltransferase(COMT) inhibitor used…Improvements in Parkinson’s disease motor complications after treatment with opicapone: results from the OPTI-ON study
Objective: To describe motor complications as measured by the Movement Disorder Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) Part IV in participants from the Opicapone Treatment…ADOPTION Study: Status update of a Randomised, Open-Label Exploratory Trial of Opicapone in Parkinson’s Disease
Objective: This study aims to evaluate the effect of once-daily opicapone (OPC) 50 mg versus an additional dose of levodopa (L-dopa)/dopa decarboxylase inhibitor (DDCi) to…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.